Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Simon Vyse & Paul H Huang. (2022) Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Review of Anticancer Therapy 22:1, pages 3-16.
Read now
Read now
Laura Pacini, Andrew D Jenks, Simon Vyse, Christopher P Wilding, Amani Arthur & Paul H Huang. (2021) Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer. Pharmacogenomics and Personalized Medicine 14, pages 301-317.
Read now
Read now
Rajan Chaudhari, Long Wolf Fong, Zhi Tan, Beibei Huang & Shuxing Zhang. (2020) An up-to-date overview of computational polypharmacology in modern drug discovery. Expert Opinion on Drug Discovery 15:9, pages 1025-1044.
Read now
Read now
Shruti Kate, Anuradha Chougule, Amit Joshi, Vanita Noronha, Vijay Patil, Rohit Dusane, Leena Solanki, Priyanka Tiwrekar, Vaishakhi Trivedi & Kumar Prabhash. (2019) Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer: Targets and Therapy 10, pages 1-10.
Read now
Read now
Articles from other publishers (20)
Xuegang Li, Pengqi Gong, Xue Zhou, Shankun Wang, Yingxuan Liu, Yanan Zhang, Linh V. Nguyen, Stephen C. Warren-Smith & Yong Zhao. (2023) In-situ detection scheme for EGFR gene with temperature and pH compensation using a triple-channel optical fiber biosensor. Analytica Chimica Acta 1263, pages 341286.
Crossref
Crossref
Asim Joshi, Ashwin Butle, Supriya Hait, Rohit Mishra, Vaishakhi Trivedi, Rahul Thorat, Anuradha Choughule, Vanita Noronha, Kumar Prabhash & Amit Dutt. (2022) Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Translational Oncology 22, pages 101461.
Crossref
Crossref
Xuegang Li, Pengqi Gong, Qiming Zhao, Xue Zhou, Yanan Zhang & Yong Zhao. (2022) Plug-in optical fiber SPR biosensor for lung cancer gene detection with temperature and pH compensation. Sensors and Actuators B: Chemical 359, pages 131596.
Crossref
Crossref
Rilan Bai, Xiao Chen, Wei Song, Huimin Tian & Jiuwei Cui. (2021) Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. Journal of Cancer Research and Clinical Oncology 148:1, pages 163-176.
Crossref
Crossref
Steven Zhang, Shu Jin, Celina Griffin, Zhongling Feng, Jianchang Lin, Mike Baratta, Rachael Brake, Karthik Venkatakrishnan & Neeraj Gupta. (2021) Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products. Clinical Pharmacology in Drug Development 10:9, pages 1028-1043.
Crossref
Crossref
Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia & Tracy Li. (2021) Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLOS ONE 16:3, pages e0247620.
Crossref
Crossref
Nishan Tchekmedyian, Bill Paxton, Francois Lebel, Lena Keossayan & John V. Heymach. (2020) Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib. JTO Clinical and Research Reports 1:4, pages 100081.
Crossref
Crossref
Juliana F. Vilachã, Sarah C. Mitchel, Muluembet Z. Akele, Stephen Evans & Matthew R. Groves. (2020) Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. Crystals 10:9, pages 725.
Crossref
Crossref
Alex M. Li, Amélie Boichard, Enriqueta Felip & Razelle Kurzrock. (2020) New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Critical Reviews in Oncology/Hematology 151, pages 102990.
Crossref
Crossref
Chia-I Shen, Hsiang-Ling Ho, Yi-Chen Yeh, Chao-Hua Chiu & Teh-Ying Chou. (2020) Epidermal growth factor receptor mutations in non–small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction–based assays. Journal of the Chinese Medical Association 83:4, pages 345-349.
Crossref
Crossref
Vinodini Merinda, Gatot Soegiarto & Laksmi Wulandari. (2020) T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Lung India 37:1, pages 13.
Crossref
Crossref
Agnes McAuliffe, Poorva Bindal, Meredith Haley & James Vredenburgh. (2019) Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation. Journal of Oncology Pharmacy Practice 26:1, pages 206-208.
Crossref
Crossref
Danilo Rocco, Ciro Battiloro, Luigi Della Gravara & Cesare Gridelli. (2019) Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond. Reviews on Recent Clinical Trials 14:2, pages 120-128.
Crossref
Crossref
Bumhee Yang, Hyun Lee, Sang-Won Um, Kyunga Kim, Jae Il Zo, Young Mog Shim, O Jung Kwon, Kyung Soo Lee, Myung-Ju Ahn & Hojoong Kim. (2019) Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations. Lung Cancer 129, pages 28-34.
Crossref
Crossref
Akhil Rajendra, Vanita Noronha, Amit Joshi, VijayMaruti Patil, Nandini Menon & Kumar Prabhash. (2019) Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. Cancer Research, Statistics, and Treatment 2:1, pages 36.
Crossref
Crossref
Andrés F. Cardona, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Helano C. Freitas, Sara T. Granados, Omar Castillo, George Oblitas, Luis Corrales, Christian D. Castro, Alejandro Ruiz-Patiño, Claudio Martín, María Angelina Pérez, Lisde González, Luis Chirinos, Carlos Vargas, Hernán Carranza, Jorge Otero, July Rodriguez, Jenny Rodriguez, Pilar Archila, Mauricio Lema, José Acosta Madiedo, Niki Karachaliu, Beatriz Wills, Luis E. Pino, Vladimir de Lima, Rafael Rosell & Oscar Arrieta. (2018) EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). Lung Cancer 125, pages 265-272.
Crossref
Crossref
Akimasa Sekine, Takuma Katano, Tsuneyuki Oda, Satoshi Ikeda, Tae Iwasawa, Hiroaki Satoh, Toshiro Kataoka, Koji Okudela & Takashi Ogura. (2018) Miliary lung metastases from non‑small cell lung cancer with Exon 20 insertion: A dismal prognostic entity: A case report. Molecular and Clinical Oncology.
Crossref
Crossref
Kim Tam Bui, Wendy A. Cooper, Steven Kao & Michael Boyer. (2018) Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine 7:8, pages 192.
Crossref
Crossref
Zachary Schrank, Gagan Chhabra, Leo Lin, Tsatsral Iderzorig, Chike Osude, Nabiha Khan, Adijan Kuckovic, Sanjana Singh, Rachel Miller & Neelu Puri. (2018) Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers 10:7, pages 224.
Crossref
Crossref
Raymond Tsz-Tong Chan. (2018) Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months’ survival. Asia-Pacific Journal of Clinical Oncology 14, pages 7-9.
Crossref
Crossref